Addressing the global challenges of organ shortage & poorly translatable in-vitro models, Cellbricks produces living tissue with its 3D-bioprinting platform. While advancing its patient-specific tissue implant, Cellbricks partners with pharmaceutic companies for tissue models. With $1M in revenue & upcoming partnerships, Cellbricks’ tissue engineering tech is poised to transform pharma & healthcare space, from lab models to cell therapies, to life-sustaining organ transplants.